Akso Health Group Receives Notice of Filing Delinquency From Nasdaq

 Akso Health Group. announced that the Company received a written notification (the “Notification”) from the Nasdaq Stock Market LLC (“Nasdaq”) on August 16, 2022, indicating the Company is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rules 5250(c)(1) since the Company has not yet filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2022 (the “Filing”) with the Securities and Exchange Commission (the “SEC”).

In accordance with Nasdaq Listing Rule 5250(c)(1), the Company has up to 60 calendar days to either cure the deficiency or to submit a plan to Nasdaq showing how it intends to regain compliance. If the plan is accepted, Nasdaq can grant the Company an exception of up to 180 calendar days from the Filing’s due date, or until February 13, 2023, to regain compliance.

The Company’s business operations are not affected by the Notification and the Company intends to either cure the deficiency or submit the plan as soon as practicable but no later than October 17, 2022. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.

About Akso Health Group

Akso Health Group Inc., formerly known as Xiaobai Maimai Inc., operates a social e-commerce platform in China that collaborates with other domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products. In addition, the Company plans to develop a new business as a cancer therapy and radiotherapy oncology service provider with operations in the U.S. The Company plans to open 2 vaccine research centers and 100 radiation oncology centers to be located on the east coast serving cancer patients in need of varying stages of treatment, including specialized radiation therapy centers for radiotherapy (RT), personalized consultation, conventional treatment planning, and other cancer related treatment services.

 

For more information, please visit ir.xiaobaimaimai.com

For investor inquiries, please contact:

The Company

Investor Relations
Ms. Zenabo Ma
Email: ir@ahgtop.com

Christensen

In China
Mr. Eric Yuan
Phone: +86-10- 5900-1548
E-mail: Eyuan@christensenir.com

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: lbergkamp@christensenir.com

Related Post
Asetek – Q3 2022: Focus on Efficiencies and New Products Amid Continued Market Headwinds
Noble Acquires Fourteen-Asset Marriott, Hilton, and Hyatt Hotel Portfolio
Harbor Associates Completes Lease-Up on Bungalows Del Mar Office in Del Mar, California Despite the Pandemic and Work from Home Trend
Bronstein, Gewirtz & Grossman, LLC Notifies TuSimple Holdings Inc. (TSP) Investors of Class Action and to Actively Participate
Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Dingdong (Cayman) Limited – DDL